Efficacy of Lebrikizumab in patients with fibrosing skin conditions- Competitive Research Grant
Lilly Immunology is committed to improving the lives of individuals living with immunological diseases and disorders. We are driven to developing innovative solutions through our broad portfolio of therapeutic agents directed at multiple targets in cytokine pathways. Through internal research programs and support of investigator initiated studies, we are dedicated to long-term partnerships that will enable us to make a real impact on individuals’ lives. Lilly is also committed to support external research in Dermatological clinical and molecular aspects affecting patients with skin of color.
AREA OF INTEREST AND PROJECT TYPES
Projects eligible for support will focus on lebrikizumab efficacy in adults and adolescents with fibrosing skin conditions such as morphea, scleroderma, and scarring alopecias (FFA, CCCA).
Projects should address a knowledge gap and avoid overlapping with ongoing or previously published studies using lebrikizumab.
Lilly is dedicated to promoting diversity in clinical trials and establishing clear, measurable goals to drive progress.
Project types may include, but are not limited to:
• Description of improvements on fibrosing skin conditions
• Evaluation of changes in fibrosing skin conditions with novel imaging methods
• Description of patient-reported outcomes and improvements in quality of life related to fibrosing skin conditions
• Photographic and clinical documentation of clinical improvements
Studies comparing lebrikizumab with other therapies are out of scope. Interventional and non-interventional trials will be taken into consideration.
FUNDING RANGE AND PROJECT LENGTH
Up to approximately $500,000 – Project length can be up to two years.
• Award amounts include all direct costs, institutional overhead, and indirect
costs.
• Grants will be distributed following a fully executed agreement and will be
based on milestones/enrollment and a final report.
• Placebo will NOT be provided for research.
ELGIBILITY
Geographic Scope:
• United States
Applicant Eligibility Criteria
• The principal investigator (Pl) must be based in the United States.
• The applicant (Pl) must have a medical or postdoctoral
degree (MD, PhD, or equivalent), an advanced nursing
degree (BSN with a MS/PhD), or a degree in Pharmacy
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.